Find policies, billing codes, payers, states, and providers
CPT 96401: Subcutaneous or Intramuscular Chemotherapy Administration
CPT code 96401 designates the provider administration of nonhormonal antineoplastic chemotherapy by subcutaneous or intramuscular injection. This code captures a discrete chemotherapy administration route that is clinically distinct from intravenous push or infusion services and is relevant for oncology practices, payers, and billing teams nationwide. Accurate use of CPT code 96401 affects claim processing, benefit determinations, and clinical documentation workflows across outpatient oncology settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for subcutaneous and intramuscular chemotherapy administration, how this service compares to related administration codes, and typical sites of care. The publication summarizes common billing relationships and situational considerations that influence coding selection and payer adjudication for parenteral chemotherapy delivered by injection.
This resource is intended to help billing managers, oncology clinicians, and revenue cycle professionals understand where 96401 fits within chemotherapy administration coding, the clinical scenarios it represents, and what to evaluate when reconciling claims and documentation. Data not available in the input for detailed reimbursement benchmarks and payer-specific policy language.
Customize your policy alerts
Sign up for cpt 96401 policy alerts
Get alerted when payer policies referencing 96401 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 96401 describes the administration of nonhormonal antineoplastic chemotherapy drugs delivered by subcutaneous or intramuscular injection to a patient. This service is clinical chemotherapy administration rather than oral or intravenous delivery.
Service type: Chemotherapy administration, subcutaneous or intramuscular
Typical site of service: Outpatient clinic, oncology infusion center, or physician office where parenteral chemotherapy injections are provided
National Reimbursement Benchmarks
Commercial averages sit well above Medicare for CPT 96401: Blue Cross Blue Shield, Aetna, Cigna, UnitedHealth Group and BUCA have mean rates clustered in the $115–$135 range, while Medicare’s mean is $74.9, creating a commercial-to-Medicare gap of roughly $40–$60. Notably, BUCA’s mean of $129.4 aligns with the higher end of commercial payers, exceeding Medicare by about $54.5.
Dispersion varies materially across payers. Calculating interquartile ranges (P75−P25) yields the tightest spread for UnitedHealth Group at $66.4 and the widest for Aetna at $79.0. Blue Cross Blue Shield shows a relatively narrow IQR of $63.5, Cigna an IQR of $78.0, and BUCA an IQR of $68.4. These differences indicate more consistent commercial payment levels for some payers versus greater variability for others.